Onchocerciasis

Summary

Onchocerciasis (MONDO:0017137) is a disease and 29 clinical trials. Top therapeutic interventions include moxidectin, ivermectin, and albendazole. A subtype of Rhabditida infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Europe)
• Clinical trials: 29

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	<1 / 1 000 000		Europe	Not yet validated
Point prevalence	>1 / 1000		Specific population	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	onchocerciasis
Mondo ID	MONDO:0017137
EFO	EFO:0007402
MeSH	D009855
Orphanet	2737
DOID	DOID:11678
ICD-10-CM	B73
ICD-11	106136071
NCIT	C34861
SNOMED CT	38539003
UMLS	C0029001
MedGen	14477
GARD	0007252
MedDRA	10030314, 10039202
Is cancer (heuristic)	no

Also known as: infection by Onchocerca volvulus · Onchocerca volvulus infection · onchocerciasis · River blindness · Robles’ disease

Disease family

This is a subtype of Rhabditida infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › Nematoda infectious disease › Rhabditida infectious disease › onchocerciasis

Related subtypes (11): thelaziasis, ancylostomiasis, Ascaridida infectious disease, enterobiasis, mansonelliasis, oesophagostomiasis, setariasis, strongyloidiasis, trichostrongylosis, dirofilariasis, dracunculiasis

Subtypes (1): ocular onchocerciasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Ivermectin	Approved (phase 4)
Moxidectin	Approved (phase 4)
Albendazole	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Azithromycin, Rifampin.

Clinical trials & evidence

Clinical trials

Clinical trials: 29.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	12
PHASE2	7
PHASE3	5
PHASE1	3
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07145736	PHASE4	RECRUITING	Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
NCT03052998	PHASE4	COMPLETED	Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
NCT03876262	PHASE3	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
NCT00790998	PHASE3	COMPLETED	Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection
NCT02078024	PHASE3	COMPLETED	Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana
NCT03238131	PHASE3	COMPLETED	IVM Alone vs ALB + IVM Against Onchocerciasis
NCT04311671	PHASE3	COMPLETED	Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
NCT05180461	PHASE2	ACTIVE_NOT_RECRUITING	Emodepside Phase II Trial for Treatment of Onchocerciasis
NCT06070116	PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
NCT00127504	PHASE2	COMPLETED	Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
NCT00300768	PHASE2	COMPLETED	Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
NCT01035619	PHASE2	WITHDRAWN	Pediatric Pharmacokinetics And Safety Study Of Moxidectin
NCT04188301	PHASE2	COMPLETED	Safety and Efficacy of IDA for Onchocerciasis
NCT04913610	PHASE2	TERMINATED	Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
NCT03962062	PHASE1	COMPLETED	A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
NCT05084560	PHASE1	TERMINATED	Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
NCT06412926	PHASE1	COMPLETED	A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants
NCT00001230	Not specified	RECRUITING	Host Response to Infection and Treatment in Filarial Diseases
NCT06350851	Not specified	RECRUITING	Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
NCT07248462	Not specified	NOT_YET_RECRUITING	Integrating Mental Health Into Neglected Tropical Disease Care in Ghana
NCT07506967	Not specified	NOT_YET_RECRUITING	Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
NCT01905436	Not specified	COMPLETED	Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
NCT02032043	Not specified	COMPLETED	Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
NCT03131401	Not specified	COMPLETED	Prevalence of LF Infection in Districts Not Included in LF Control Activities
NCT03517462	Not specified	COMPLETED	Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
NCT03653975	Not specified	UNKNOWN	Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District
NCT04035174	Not specified	WITHDRAWN	Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
NCT05749653	Not specified	COMPLETED	Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area
NCT05750043	Not specified	COMPLETED	Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MOXIDECTIN	4	8
IVERMECTIN	4	7
ALBENDAZOLE	4	4
DIETHYLCARBAMAZINE	4	2
RIFAMPIN	4	1
EMODEPSIDE	2	2
FLUBENTYLOSIN	2	1
AWZ-1066S	1	1
CHEMBL263291	0	9
CHEMBL4782609	0	8
CHEMBL5280985	0	8
CHEMBL4082099	0	7
CHEMBL4788951	0	7